JP2024542823A5 - - Google Patents

Info

Publication number
JP2024542823A5
JP2024542823A5 JP2024533832A JP2024533832A JP2024542823A5 JP 2024542823 A5 JP2024542823 A5 JP 2024542823A5 JP 2024533832 A JP2024533832 A JP 2024533832A JP 2024533832 A JP2024533832 A JP 2024533832A JP 2024542823 A5 JP2024542823 A5 JP 2024542823A5
Authority
JP
Japan
Application number
JP2024533832A
Other languages
Japanese (ja)
Other versions
JPWO2023107957A5 (https=
JP2024542823A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/081031 external-priority patent/WO2023107957A1/en
Publication of JP2024542823A publication Critical patent/JP2024542823A/ja
Publication of JP2024542823A5 publication Critical patent/JP2024542823A5/ja
Publication of JPWO2023107957A5 publication Critical patent/JPWO2023107957A5/ja
Pending legal-status Critical Current

Links

JP2024533832A 2021-12-06 2022-12-06 アンタゴニスト抗npr1抗体およびその使用方法 Pending JP2024542823A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163286476P 2021-12-06 2021-12-06
US63/286,476 2021-12-06
US202263310078P 2022-02-14 2022-02-14
US63/310,078 2022-02-14
PCT/US2022/081031 WO2023107957A1 (en) 2021-12-06 2022-12-06 Antagonist anti-npr1 antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2024542823A JP2024542823A (ja) 2024-11-15
JP2024542823A5 true JP2024542823A5 (https=) 2026-01-28
JPWO2023107957A5 JPWO2023107957A5 (https=) 2026-01-28

Family

ID=85017755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533832A Pending JP2024542823A (ja) 2021-12-06 2022-12-06 アンタゴニスト抗npr1抗体およびその使用方法

Country Status (11)

Country Link
US (1) US12606618B2 (https=)
EP (1) EP4444416A1 (https=)
JP (1) JP2024542823A (https=)
KR (1) KR20240112973A (https=)
AU (1) AU2022408149A1 (https=)
CA (1) CA3239802A1 (https=)
CL (2) CL2024001632A1 (https=)
CO (1) CO2024008879A2 (https=)
IL (1) IL313265A (https=)
MX (1) MX2024006812A (https=)
WO (1) WO2023107957A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY205168A (en) 2018-10-23 2024-10-04 Regeneron Pharma Anti-npr1 antibodies and uses thereof
US12325752B2 (en) 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU2001268427B2 (en) * 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004011618A2 (en) 2002-07-29 2004-02-05 Hmgene, Inc. Methods of identifying adipocyte specific genes, the genes identified, and their uses
US20080214437A1 (en) 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
EP2162464A1 (en) 2007-06-06 2010-03-17 Boehringer Ingelheim International GmbH Natriuretic fusion proteins
US9090695B2 (en) 2008-12-03 2015-07-28 Morphosys Ag Antibodies for guanylyl cyclase receptors
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
CN102482715A (zh) 2009-07-13 2012-05-30 霍夫曼-拉罗奇有限公司 用于癌症治疗的诊断方法和组合物
SI2501817T2 (sl) 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US9451770B2 (en) 2012-06-08 2016-09-27 Charles Despres Method of activating immune response in plants
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
US9987330B2 (en) * 2013-12-05 2018-06-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating or preventing pruritis by blocking natriuretic polypeptide B
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016131943A1 (en) 2015-02-20 2016-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes
WO2017209553A2 (ko) 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 환자 유래 세포를 이용한 항체 스크리닝 방법
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
US20190135804A1 (en) * 2017-11-03 2019-05-09 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Compositions and methods for the inhibition of pruritus
KR102780406B1 (ko) * 2018-02-01 2025-03-17 화이자 인코포레이티드 Cd70을 표적으로 하는 키메라 항원 수용체
MY205168A (en) 2018-10-23 2024-10-04 Regeneron Pharma Anti-npr1 antibodies and uses thereof
EP3898700A1 (en) 2018-12-18 2021-10-27 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
AU2020241896A1 (en) * 2019-03-20 2021-09-23 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
EA202193345A1 (ru) * 2019-06-12 2022-03-16 Новартис Аг Антитела к рецептору-1 натрийуретического пептида и способы их применения
EP4259661A1 (en) * 2020-12-14 2023-10-18 Novartis AG Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
US12325752B2 (en) 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists
JP2024505636A (ja) * 2021-01-15 2024-02-07 ザ ロックフェラー ユニバーシティー 抗sars-cov-2中和抗体
IL311917A (en) 2021-10-11 2024-06-01 Regeneron Pharma Methods for Inducing Hemodynamic Change by Administering an Anti-NPR1 Antibody

Similar Documents

Publication Publication Date Title
JP2024542823A5 (https=)
BR102022025291A2 (https=)
CL2025003880A1 (es) Perforadora de roca y método para manipular las brocas.
BY13176U (https=)
BY13141U (https=)
BY13168U (https=)
BY13167U (https=)
BY13166U (https=)
BY13165U (https=)
BY13164U (https=)
BY13163U (https=)
BY13162U (https=)
BY13161U (https=)
BY13160U (https=)
BY13159U (https=)
BY13158U (https=)
BY13157U (https=)
BY13156U (https=)
BY13155U (https=)
CN307050103S (https=)
BY13153U (https=)
CN307049814S (https=)
BY13152U (https=)
CN307049475S (https=)
BY13174U (https=)